Evidence map›Paper›PMID 35793042›Full record

ReviewEuropean journal of drug metabolism and pharmacokinetics2022

Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Anna Zerdoug, Marc Le Vée, Shotaro Uehara, Béatrice Lopez, Christophe Chesné, Hiroshi Suemizu, Olivier Fardel

Abstract readReview
PubMed Publisher
In one paragraph

Review in European journal of drug metabolism and pharmacokinetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Anna ZerdougUniversity of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, 35000, Rennes, France.
Marc Le VéeUniversity of Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, 35000, Rennes, France.
Shotaro UeharaCentral Institute for Experimental Animals, Kawasaki, 210-0821, Japan.
Béatrice LopezBiopredic International, 35760, Saint Grégoire, France.
Christophe ChesnéBiopredic International, 35760, Saint Grégoire, France.
Hiroshi SuemizuCentral Institute for Experimental Animals, Kawasaki, 210-0821, Japan.
Olivier FardelUniversity of Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Faculté de Pharmacie, 2 Avenue du Pr Léon Bernard, 35043, Rennes, France. olivier.fardel@univ-rennes1.fr.ORCID http://orcid.org/0000-0001-5657-4255
Inserm · FRBiopredic (France) · FRCentral Institute for Experimental Animals · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chimeric mice with humanized livers constitute an attractive emergent experimental model for investigating human metabolism and disposition of drugs. The present review was designed to summarize key findings about the use of this model for studying human hepatic drug transporters, which are now recognized as important players in pharmacokinetics and consequently have to be considered from a regulatory perspective during pharmaceutical drug development. The reviewed data indicate that chimeric mice with humanized livers have been successfully used for analysing the implications of human hepatic drug transporters for drug hepatobiliary elimination, drug-drug interactions and drug-induced cholestasis. Such transporter studies have been performed in vivo with chimeric mice and/or in vitro with human hepatocytes isolated from humanized liver and used either in suspension or in culture. The residual presence of mouse hepatocytes and the potential morphological/histological alterations of the humanized liver, as well as its immunodeficient mouse environment, have, however, to be considered when using chimeric mice with humanized livers for transporter studies. Finally, if the proof of concept of applying chimeric mice with humanized livers to hepatic drug transport is established, more experimental data on this topic, including from standardization approaches, are likely required to completely and accurately demonstrate the robustness, convenience and added value of this chimeric mouse model for drug transporter studies.

Indexed as

HepatocytesLiverAnimalsChimeraHumansMembrane Transport ProteinsMetabolic Clearance RateMiceMembrane Transport Proteins

Identifiers

PMID35793042
OpenAlexW4283833259

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.